811 material Form 8-K filings that 685 companies we cover made with the SEC in April 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
RPC, Inc. completed its purchase of Pintail Alternative Energy, a Permian Basin wireline services provider, on April 1, 2025, for a purchase price of $245 million. The cash portion came from RPC's cash on hand, and the rest was paid in restricted RPC stock and a $50 million seller note, which adds a future debt obligation for shareholders to track.
Purchase price of $245 million: about $170 million cash, $25 million in restricted RPC stock (4,545,454 shares), and a $50 million secured seller note
Seller note repayments: $20 million on the first anniversary, $10 million on the second, and the remaining principal on the third; interest is SOFR plus 2.0%
Pintail's full-year 2024 revenue was approximately $409 million, according to RPC's press release
Approximately $2 million of the cash payment is in escrow, pending final closing adjustments
PVH Corp. signed a credit agreement on April 4, 2025, providing a $250.0 million delayed-draw term loan facility that was undrawn at closing. The company can borrow under the facility for working capital or general corporate purposes, and the filing gives no indication of the loan being used so far, so the deal adds available borrowing capacity rather than existing debt.
Facility: $250.0 million senior, unsecured delayed-draw term loans, with Barclays Bank PLC as administrative agent
Borrowings: up to four draws before February 4, 2026, each with a $50.0 million minimum; term loans mature April 3, 2026
Pricing: initial margin of 1.125% over term SOFR or 0.125% over base rate, plus a 0.125% commitment fee starting on the 91st day
Arthur J. Gallagher & Co. amended and restated its credit agreement on April 3, 2025, increasing total commitments from $1.7 billion to $2.5 billion and extending the maturity date from June 22, 2028 to April 3, 2030. The filing also allows commitments to be increased up to $3 billion, and other key terms, including financial ratios and all-in drawn pricing, were not changed.
Commitments rise from $1.7 billion to $2.5 billion, including a $75 million letter of credit sub-facility and a $250 million Euro swingline sub-facility.
Maturity extended from June 22, 2028 to April 3, 2030.
Commitments may be increased up to $3 billion with agreement from lenders or additional banks.
Financial ratios and all-in drawn pricing were not changed; facility fee and applicable margin were updated based on the company's long-term senior unsecured debt rating.
Unitil Corporation agreed on March 31, 2025 to acquire all outstanding shares of Maine Natural Gas Company from Avangrid Enterprises for $86.0 million in cash, subject to certain adjustments. The deal is subject to approval by the Maine Public Utilities Commission and is expected to close by the end of 2025, with the purchase to be funded by a $86.0 million delayed-draw term loan from The Bank of Nova Scotia. The company says the acquisition is expected to be earnings accretive over the long term and to support its long-term earnings per share growth of 5% to 7%.
Purchase price is $86.0 million in cash on a debt-free basis, subject to adjustment for closing working capital and transaction expenses; the agreement includes no escrow or holdback
Closing requires an order from the Maine Public Utilities Commission and is expected by the end of 2025
Debt commitment letter from The Bank of Nova Scotia provides a $86.0 million senior unsecured delayed-draw term loan with a maturity of the first anniversary of closing, and includes a 65% debt to capitalization ratio covenant tested quarte
Maine Natural serves approximately 6,300 residential and commercial natural gas customers and had an estimated $69.0 million of rate base as of December 31, 2024
At its April 4, 2025 Investor Day, DigitalOcean reaffirmed its guidance for the quarter ended March 31, 2025 and the year ending December 31, 2025, as first issued in its February 25, 2025 earnings release. The filing reports no new financial figures, so the outlook is unchanged and shareholders get no updated numbers from this filing.
Guidance for the quarter ended March 31, 2025 and fiscal year 2025 was reaffirmed, not changed.
Guidance was originally issued in the February 25, 2025 press release on fiscal Q4 and full-year 2024 results.
A webcast replay and presentation materials are available on the investor relations website until April 3, 2026.
Effective March 31, 2025, CVR Energy appointed Robert E. Flint and Colin Kwak to its board, with Flint named chairperson, and Ted Papapostolou resigned from the board and its committees for personal reasons. Both new directors are employed by Icahn Enterprises or its affiliates, which indirectly owns approximately 68% of the company's common stock, so the change adds IEP-affiliated representation to the board that already reflects that controlling stake.
Robert E. Flint appointed to the board and named Chairperson, and to the Special Committee, effective March 31, 2025
Colin Kwak appointed to the board, the Compensation Committee, and the Nominating and Corporate Governance Committee, effective March 31, 2025
Ted Papapostolou resigned from the board and its committees effective March 31, 2025, citing personal reasons
Board size increased from seven to eight directors; IEP owns approximately 68% of outstanding common stock
On March 31 and March 26, 2025, subsidiary AJR Enterprises signed two supply agreements with Sage Products, LLC (Stryker), the company's second-largest customer. Stryker agreed to buy 100% of its requirements for certain products from AJR on an exclusive basis, and the company agreed to buy the equipment needed to make them and to move that manufacturing to the Dominican Republic over two years. The filing does not disclose revenue or dollar amounts for the agreements.
March 31, 2025 agreement: exclusive purchase commitment for a 42-month period starting January 1, 2026.
March 26, 2025 amended agreement: exclusive purchase commitment for about 63 months, effective April 24, 2024.
Company will move manufacturing to the Dominican Republic over the next two years; Stryker is eligible for price reductions as products transfer.
Stryker's purchase requirement ends if certain events occur, such as the company failing to meet regulatory or quality requirements.
On April 1, 2025, MSA Safety entered a Fifth Amended and Restated Credit Agreement with PNC Bank as administrative agent, replacing its prior 2021 credit agreement. The unsecured revolving facility allows borrowing up to $1.3 billion and runs through April 1, 2030, and the company also amended two note purchase agreements to match the new covenants. For shareholders, the filing shows a refreshed borrowing facility with covenants and a change-of-control default, but it does not disclose any amount drawn.
Maximum outstanding borrowings of $1.3 billion, with up to an additional $500 million available through lender increases subject to board and lender approval
Facility term expires April 1, 2030, replacing the Fourth Amended and Restated Credit Agreement dated May 24, 2021
Financial covenants require a fixed charges coverage ratio of at least 1.50 to 1.00 and a net leverage ratio of no more than 3.50 to 1.00 (4.00 to 1.00 during certain acquisition periods)
Amendments to the Prudential and NYL note agreements, dated April 1, 2025, conform their covenants to the new credit agreement
Renasant Corporation completed its merger with The First Bancshares, Inc. on April 1, 2025, with each First share converted into 1.00 Renasant share. Renasant also assumed $133,786,000 of subordinated debentures and notes, and its board grew to 17 directors, while Executive Chairman E. Robinson McGraw agreed to resign as an officer effective May 1, 2025, when Kevin D. Chapman becomes Chief Executive Officer.
Merger completed April 1, 2025; each First share converted into 1.00 Renasant share, with cash paid in lieu of fractional shares
Renasant assumed subordinated debentures and notes totaling $133,786,000 in aggregate principal amount
Board increased to 17 directors with four new seats filled by M. Ray (Hoppy) Cole, Jr., Jonathan A. Levy, Renee Moore and Ted E. Parker
E. Robinson McGraw will resign as an officer effective May 1, 2025; Kevin D. Chapman becomes CEO on that date, and McGraw has a $672,185.55 severance payment
Cintas said Chief Financial Officer Mike Hansen will retire from the CFO role and become Assistant to the CEO effective May 31, 2025. Scott Garula, President of the Rental Division, was appointed to succeed him as Executive Vice President and CFO effective June 1, 2025, a planned transition the company describes as following a succession process.
Mike Hansen retires as Executive Vice President and CFO; he notified the company on March 31, 2025, and moves to Assistant to the CEO effective May 31, 2025
Scott Garula, 54, was appointed on April 1, 2025 as Executive Vice President and CFO effective June 1, 2025; he joined Cintas in 1996 and was President and COO of the Rental Division from June 2023
Garula's initial annual pay: $650,000 base salary, 90% of base salary target annual incentive, and $1,500,000 target long-term incentive
One-time promotion awards under the 2016 Equity Plan: restricted stock with $250,000 and non-qualified stock options with $75,000 grant date fair value
Neurocrine Biosciences said Sanjay Keswani, M.D., will succeed Eiry W. Roberts, M.D., as Chief Medical Officer effective June 2, 2025. Dr. Roberts, who has held the role for seven years, will remain with the company in a strategic advisory role. The change replaces a long-serving clinical leader with an executive who has more than 20 years of pharmaceutical industry experience.
Sanjay Keswani, M.D., agreed on April 2, 2025 to become Chief Medical Officer, effective June 2, 2025
Dr. Keswani succeeds Eiry W. Roberts, M.D., who has served as CMO for the past seven years
Dr. Roberts previously announced her retirement in July 2023 and will stay on in a strategic advisory role
Dr. Keswani was previously President and CEO of ImmunoBrain and held R&D roles at Hoffmann-La Roche and Bristol-Myers Squibb
RB Global entered into an amended and restated credit agreement on April 3, 2025, with Bank of America, N.A. as administrative agent. The deal provides up to $1.3 billion in multi-currency revolving credit and a term loan A facility, both scheduled to mature in April 2030. The filing does not report earnings or guidance, so its effect on shareholders is mainly a change in the company's debt terms.
Revolving credit facilities of up to $1.3 billion in aggregate principal amount
Term loan A facility of a $950 million USD tranche and a CAD$102.5 million Canadian dollar tranche
Both facilities are scheduled to mature in April 2030
Company must keep a consolidated leverage ratio of 4.00 to 1.00, adjustable upward by 0.50 for four quarters after certain permitted acquisitions
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.